Evidence map›Paper›PMID 39434478›Full record

ArticleAdvanced healthcare materials2024

Artificial Internalizing Receptors: Intracellular Delivery of Cargo Through Bio-Orthogonal Recognition.

Ane Bretschneider Søgaard, Rikke Fabech Hansson, Anne Selch Tvilum, Alexander N Zelikin

Abstract read
In one paragraph

Article in Advanced healthcare materials, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Ane Bretschneider SøgaardiNano Interdisciplinary Nanoscience Center, Aarhus University, Aarhus, 8000, Denmark.
Rikke Fabech HanssonDepartment of Chemistry, Aarhus University, Aarhus, 8000, Denmark.
Anne Selch TvilumDepartment of Chemistry, Aarhus University, Aarhus, 8000, Denmark.
Alexander N ZelikiniNano Interdisciplinary Nanoscience Center, Aarhus University, Aarhus, 8000, Denmark.ORCID 0000-0002-9864-321X

Funding

Danmarks Frie Forskningsfond 0135-00162BDanmarks Frie Forskningsfond 9041-00242ANovo Nordisk Fonden NNF20OC0062131
6 · The paper itself

Abstract

Drug targeting is a methodology that helps to overcome the side effects of therapeutic molecules. However, insufficient targeting specificity and the on-target/off-site delivery leave much room for improvement in the targeting endeavors. One approach to enhance the specificity of drug targeting is to engineer artificial receptors with recognition ligands not observed in nature. To this end, artificial internalizing receptors that feature cholesterylamine as the artificial pull-in mechanism, and an anti-fluorescein antibody as the exofacial recognition and capture tool are developed. Fluorescein labeling is among the most routine techniques in biochemistry and can readily provide a way to make cognate derivatives for receptor-mediated endocytosis using these artificial receptors. Herein, the synthesis and the structure-activity relationship for these artificial receptors are detailed, their potency and efficacy in mediating drug delivery for the antibody-drug conjugates are illustrated, and the scope and limitations of targeting the chemically engineered cells via artificial receptors are investigated. Taken together, the presented data explore an innovative approach to drug targeting and contribute to the development of techniques in cell engineering using the tools of chemistry.

Indexed as

Drug Delivery SystemsReceptors, ArtificialAnimalsEndocytosisFluoresceinHumansImmunoconjugatesFluoresceinImmunoconjugatesReceptors, Artificialartificial receptorschemical cell engineeringhapteninternalization

Identifiers

PMID39434478
PMCPMC11670270

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.